<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37405441</PMID><DateCompleted><Year>2023</Year><Month>08</Month><Day>18</Day></DateCompleted><DateRevised><Year>2023</Year><Month>08</Month><Day>23</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1437-160X</ISSN><JournalIssue CitedMedium="Internet"><Volume>43</Volume><Issue>10</Issue><PubDate><Year>2023</Year><Month>Oct</Month></PubDate></JournalIssue><Title>Rheumatology international</Title><ISOAbbreviation>Rheumatol Int</ISOAbbreviation></Journal><ArticleTitle>The relationship of neutrophil-to-lymphocyte ratio with health-related quality of life, depression, and disease activity in SLE: a cross-sectional study.</ArticleTitle><Pagination><StartPage>1841</StartPage><EndPage>1848</EndPage><MedlinePgn>1841-1848</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s00296-023-05381-8</ELocationID><Abstract><AbstractText>The neutrophil-to-lymphocyte ratio (NLR) emerged as a potential biomarker in SLE, but its association with several outcomes remains unclear. We aimed to evaluate the relationship between NLR and SLE disease activity, damage, depression, and health-related quality of life. A cross-sectional study was conducted, including 134 patients with SLE who visited the Division of Rheumatology between November 2019 and June 2021. Demographics and clinical data including NLR, Safety of Estrogens in Lupus Erythematosus National Assessment-Systemic Lupus disease activity index (SELENA-SLEDAI), Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index (SDI), physician global assessment (PhGA), patient global assessment (PGA), patient health questionnaire (PHQ)-9, patient self-rated health, and lupus quality of life (LupusQoL) scores, were collected. Patients were stratified into two groups and compared using the NLR cut-off of 2.73, the 90th percentile value of healthy individuals. The analysis included t-test for continuous variables, &#x3c7;<sup>2</sup>-test for categorical variables, and logistic regression adjusting for age, sex, BMI, and glucocorticoid use. Among the 134 SLE patients, 47 (35%) had an NLR&#x2009;&#x2265;&#x2009;2.73. The NLR&#x2009;&#x2265;&#x2009;2.73 group had significantly higher rates of severe depression (PHQ&#x2009;&#x2265;&#x2009;15), poor/fair self-rated health, and the presence of damage (SDI&#x2009;&#x2265;&#x2009;1). These patients also scored significantly lower in LupusQoL domains (physical health, planning, and body image), and higher in SELENA-SLEDAI, PhGA, and PGA. Logistic regression confirmed that high NLR is associated with severe depression (PHQ&#x2009;&#x2265;&#x2009;15) (OR:7.23, 2.03-25.74), poor/fair self-rated health (OR:2.77,1.29-5.96), high SELENA-SLEDAI score(&#x2265;&#x2009;4) (OR:2.22,1.03-4.78), high PhGA (&#x2265;&#x2009;2) (OR:3.76, 1.56-9.05), and presence of damage (SDI&#x2009;&#x2265;&#x2009;1) (OR:2.67, 1.11-6.43). High NLR in SLE may indicate depression, worse quality of life, active disease, and the presence of damage.</AbstractText><CopyrightInformation>&#xa9; 2023. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Papachristodoulou</LastName><ForeName>Eleni</ForeName><Initials>E</Initials><Identifier Source="ORCID">0000-0002-9726-7144</Identifier><AffiliationInfo><Affiliation>Department of Medicine, University of Cyprus Medical School, Nicosia, Cyprus.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medicine, University of Patras School of Health Sciences, Patras, Greece.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kakoullis</LastName><ForeName>Loukas</ForeName><Initials>L</Initials><Identifier Source="ORCID">0000-0001-6245-1569</Identifier><AffiliationInfo><Affiliation>Department of Internal Medicine, Mount Auburn Hospital, Cambridge, MA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Harvard Medical School, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Christophi</LastName><ForeName>Costas</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0003-0503-1538</Identifier><AffiliationInfo><Affiliation>Department of Biostatistics and Epidemiology, Cyprus University of Technology, Limassol, Cyprus.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Psarelis</LastName><ForeName>Savvas</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0002-1447-515X</Identifier><AffiliationInfo><Affiliation>Department of Rheumatology, Nicosia General Hospital, University of Cyprus Medical School, Nicosia, Cyprus.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hajiroussos</LastName><ForeName>Victor</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Ygia Polyclinic Hospital, Limassol, Cyprus.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Parperis</LastName><ForeName>Konstantinos</ForeName><Initials>K</Initials><Identifier Source="ORCID">0000-0001-6009-0130</Identifier><AffiliationInfo><Affiliation>Department of Internal Medicine, Division of Rheumatology, University of Cyprus Medical School, Palaios Dromos Lefkosias Lemesou No. 215/6, Aglantzia, 2029, Nicosia,, Cyprus. parperis.konstantinos-marinos@ucy.ac.cy.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>07</Month><Day>05</Day></ArticleDate></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>Rheumatol Int</MedlineTA><NlmUniqueID>8206885</NlmUniqueID><ISSNLinking>0172-8172</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011788" MajorTopicYN="Y">Quality of Life</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008180" MajorTopicYN="Y">Lupus Erythematosus, Systemic</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003430" MajorTopicYN="N">Cross-Sectional Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003863" MajorTopicYN="N">Depression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009504" MajorTopicYN="N">Neutrophils</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Biomarker</Keyword><Keyword MajorTopicYN="N">Depression</Keyword><Keyword MajorTopicYN="N">Quality of life</Keyword><Keyword MajorTopicYN="N">Systemic lupus erythematosus</Keyword></KeywordList><CoiStatement>Authors E.P, L.K, CC, SP, VH, KP declare that they have no conflict of interest. None of the authors has any financial or non-financial interests that are directly or indirectly related to the work submitted for this publication to disclose.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>5</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>6</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>8</Month><Day>18</Day><Hour>6</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>7</Month><Day>5</Day><Hour>13</Hour><Minute>5</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>7</Month><Day>5</Day><Hour>11</Hour><Minute>5</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37405441</ArticleId><ArticleId IdType="pmc">PMC10435585</ArticleId><ArticleId IdType="doi">10.1007/s00296-023-05381-8</ArticleId><ArticleId IdType="pii">10.1007/s00296-023-05381-8</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Song M, Graubard BI, Rabkin CS. Engels EA (2021) Neutrophil-to-lymphocyte ratio and mortality in the United States general population. Sci Reports. 2021;111(11):1&#x2013;9. doi: 10.1038/s41598-020-79431-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-020-79431-7</ArticleId><ArticleId IdType="pmc">PMC7801737</ArticleId><ArticleId IdType="pubmed">33431958</ArticleId></ArticleIdList></Reference><Reference><Citation>Angkananard T, Anothaisintawee T, McEvoy M, et al. Neutrophil lymphocyte ratio and cardiovascular disease risk: a systematic review and meta-analysis. Biomed Res Int. 2018;2018:2703518. doi: 10.1155/2018/2703518.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2018/2703518</ArticleId><ArticleId IdType="pmc">PMC6252240</ArticleId><ArticleId IdType="pubmed">30534554</ArticleId></ArticleIdList></Reference><Reference><Citation>Templeton AJ, McNamara MG, &#x160;eruga B, et al. Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors: a systematic review and meta-analysis. JNCI J Natl Cancer Inst. 2014 doi: 10.1093/JNCI/DJU124.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/JNCI/DJU124</ArticleId><ArticleId IdType="pubmed">24875653</ArticleId></ArticleIdList></Reference><Reference><Citation>Liang P, Yu F. Value of CRP, PCT, and NLR in prediction of severity and prognosis of patients with bloodstream infections and sepsis. Front Surg. 2022;9:857218. doi: 10.3389/fsurg.2022.857218.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fsurg.2022.857218</ArticleId><ArticleId IdType="pmc">PMC8957078</ArticleId><ArticleId IdType="pubmed">35345421</ArticleId></ArticleIdList></Reference><Reference><Citation>Jung J-Y, Lee E, Suh C-H, Kim H-A. Neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio are associated with disease activity in polymyalgia rheumatica. J Clin Lab Anal. 2019;33:e23000. doi: 10.1002/jcla.23000.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jcla.23000</ArticleId><ArticleId IdType="pmc">PMC6868401</ArticleId><ArticleId IdType="pubmed">31402523</ArticleId></ArticleIdList></Reference><Reference><Citation>Mercan R, Bitik B, Tufan A, et al. The association between neutrophil/lymphocyte ratio and disease activity in rheumatoid arthritis and ankylosing spondylitis. J Clin Lab Anal. 2016;30:597&#x2013;601. doi: 10.1002/jcla.21908.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jcla.21908</ArticleId><ArticleId IdType="pmc">PMC6807125</ArticleId><ArticleId IdType="pubmed">26666737</ArticleId></ArticleIdList></Reference><Reference><Citation>Yolbas S, Yildirim A, Gozel N, et al. Hematological indices may be useful in the diagnosis of systemic lupus erythematosus and in determining disease activity in beh&#xe7;et&#x2019;s disease. Med Princ Pract Int J Kuwait Univ Heal Sci Cent. 2016;25:510&#x2013;516. doi: 10.1159/000447948.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000447948</ArticleId><ArticleId IdType="pmc">PMC5588503</ArticleId><ArticleId IdType="pubmed">27348861</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma L, Zeng A, Chen B, et al. Neutrophil to lymphocyte ratio and platelet to lymphocyte ratio in patients with systemic lupus erythematosus and their correlation with activity: a meta-analysis. Int Immunopharmacol. 2019;76:105949. doi: 10.1016/J.INTIMP.2019.105949.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/J.INTIMP.2019.105949</ArticleId><ArticleId IdType="pubmed">31634817</ArticleId></ArticleIdList></Reference><Reference><Citation>Qin B, Ma N, Tang Q, et al. Neutrophil to lymphocyte ratio (NLR) and platelet to lymphocyte ratio (PLR) were useful markers in assessment of inflammatory response and disease activity in SLE patients. Mod Rheumatol. 2016;26:372&#x2013;376. doi: 10.3109/14397595.2015.1091136.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/14397595.2015.1091136</ArticleId><ArticleId IdType="pubmed">26403379</ArticleId></ArticleIdList></Reference><Reference><Citation>Soliman WM, Sherif NM, Ghanima IM, EL-Badawy MA. Neutrophil to lymphocyte and platelet to lymphocyte ratios in systemic lupus erythematosus: relation with disease activity and lupus nephritis. Reumatol Clin. 2018 doi: 10.1016/j.reuma.2018.07.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.reuma.2018.07.008</ArticleId><ArticleId IdType="pubmed">30166230</ArticleId></ArticleIdList></Reference><Reference><Citation>Firizal AS, Sugianli AK, Hamijoyo L. Cut off point of neutrophil-to-lymphocyte ratio as a marker of active disease in systemic lupus erythematosus. Lupus. 2020;29:1566&#x2013;1570. doi: 10.1177/0961203320950822.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0961203320950822</ArticleId><ArticleId IdType="pubmed">32807022</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu Y, Chen Y, Yang X, et al. Neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) were associated with disease activity in patients with systemic lupus erythematosus. Int Immunopharmacol. 2016;36:94&#x2013;99. doi: 10.1016/j.intimp.2016.04.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.intimp.2016.04.006</ArticleId><ArticleId IdType="pubmed">27111516</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu J, Zeng T, Wu Y, et al. Neutrophil-to-C3 ratio and neutrophil-to-lymphocyte ratio were associated with disease activity in patients with systemic lupus erythematosus. J Clin Lab Anal. 2019;33:6&#x2013;10. doi: 10.1002/jcla.22633.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jcla.22633</ArticleId><ArticleId IdType="pmc">PMC6430331</ArticleId><ArticleId IdType="pubmed">30129188</ArticleId></ArticleIdList></Reference><Reference><Citation>Parperis K, Psarelis S, Chatzittofis A, et al. Association of clinical characteristics, disease activity and health-related quality of life in SLE patients with major depressive disorder. Rheumatology (Oxford) 2021;60:5369&#x2013;5378. doi: 10.1093/RHEUMATOLOGY/KEAB123.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/RHEUMATOLOGY/KEAB123</ArticleId><ArticleId IdType="pubmed">33547787</ArticleId></ArticleIdList></Reference><Reference><Citation>Kernder A, Elefante E, Chehab G, et al. The patient&#x2019;s perspective: are quality of life and disease burden a possible treatment target in systemic lupus erythematosus? Rheumatology (Oxford) 2020;59:v63. doi: 10.1093/RHEUMATOLOGY/KEAA427.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/RHEUMATOLOGY/KEAA427</ArticleId><ArticleId IdType="pmc">PMC7719037</ArticleId><ArticleId IdType="pubmed">33280017</ArticleId></ArticleIdList></Reference><Reference><Citation>Gomez A, Qiu V, Cederlund A, et al. Adverse health-related quality of life outcome despite adequate clinical response to treatment in systemic lupus erythematosus. Front Med. 2021;8:471. doi: 10.3389/FMED.2021.651249/BIBTEX.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/FMED.2021.651249/BIBTEX</ArticleId><ArticleId IdType="pmc">PMC8085308</ArticleId><ArticleId IdType="pubmed">33937290</ArticleId></ArticleIdList></Reference><Reference><Citation>Izadi Z. Health-related quality of life measures in adult systemic lupus erythematosus. Arthritis Care Res. 2020;72:577&#x2013;592. doi: 10.1002/ACR.24245.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ACR.24245</ArticleId><ArticleId IdType="pubmed">33091273</ArticleId></ArticleIdList></Reference><Reference><Citation>Julian LJ, Yelin E, Yazdany J, et al. Depression, medication adherence, and service utilization in systemic lupus erythematosus. Arthritis Care Res (Hoboken) 2009;61:240&#x2013;246. doi: 10.1002/ART.24236.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ART.24236</ArticleId><ArticleId IdType="pmc">PMC2875189</ArticleId><ArticleId IdType="pubmed">19177526</ArticleId></ArticleIdList></Reference><Reference><Citation>Von Elm E, Altman DG, Egger M, et al. The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies. PLoS Med. 2007;4:1623&#x2013;1627. doi: 10.1371/JOURNAL.PMED.0040296.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/JOURNAL.PMED.0040296</ArticleId><ArticleId IdType="pmc">PMC2020495</ArticleId><ArticleId IdType="pubmed">17941714</ArticleId></ArticleIdList></Reference><Reference><Citation>Petri M, Orbai AMAG. Derivation and validation of systemic lupus international. Arthritis Rheum. 2012;64:2677&#x2013;2686. doi: 10.1002/art.34473.Derivation.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.34473.Derivation</ArticleId><ArticleId IdType="pmc">PMC3409311</ArticleId><ArticleId IdType="pubmed">22553077</ArticleId></ArticleIdList></Reference><Reference><Citation>Han BK, Wysham KD, Cain KC, et al. Neutrophil and lymphocyte counts are associated with different immunopathological mechanisms in systemic lupus erythematosus. Lupus Sci Med. 2020;7:7&#x2013;12. doi: 10.1136/lupus-2020-000382.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/lupus-2020-000382</ArticleId><ArticleId IdType="pmc">PMC7247402</ArticleId><ArticleId IdType="pubmed">32444416</ArticleId></ArticleIdList></Reference><Reference><Citation>Buyon JP, Petri MA, Kim MY, et al. The effect of combined estrogen and progesterone hormone replacement therapy on disease activity in systemic lupus erythematosus: a randomized trial. Ann Intern Med. 2005;142:953&#x2013;962. doi: 10.7326/0003-4819-142-12_part_1-200506210-00004.</Citation><ArticleIdList><ArticleId IdType="doi">10.7326/0003-4819-142-12_part_1-200506210-00004</ArticleId><ArticleId IdType="pubmed">15968009</ArticleId></ArticleIdList></Reference><Reference><Citation>Gladman D, Ginzler E, Goldsmith C, et al. The development and initial validation of the systemic lupus international collaborating clinics/American college of rheumatology damage index for systemic lupus erythematosus. Arthritis Rheum. 1996;39:363&#x2013;369. doi: 10.1002/art.1780390303.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.1780390303</ArticleId><ArticleId IdType="pubmed">8607884</ArticleId></ArticleIdList></Reference><Reference><Citation>Hyphantis T, Kotsis K, Voulgari PV, et al. Diagnostic accuracy, internal consistency, and convergent validity of the Greek version of the patient health questionnaire 9 in diagnosing depression in rheumatologic disorders. Arthritis Care Res (Hoboken) 2011;63:1313&#x2013;1321. doi: 10.1002/acr.20505.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/acr.20505</ArticleId><ArticleId IdType="pubmed">21618450</ArticleId></ArticleIdList></Reference><Reference><Citation>Kroenke K, Spitzer RL, Williams JB. The PHQ-9: validity of a brief depression severity measure. J Gen Intern Med. 2001;16:606&#x2013;613. doi: 10.1046/j.1525-1497.2001.016009606.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/j.1525-1497.2001.016009606.x</ArticleId><ArticleId IdType="pmc">PMC1495268</ArticleId><ArticleId IdType="pubmed">11556941</ArticleId></ArticleIdList></Reference><Reference><Citation>Azizoddin DR, Jolly M, Arora S, et al. Patient-reported outcomes predict mortality in lupus. Arthritis Care Res (Hoboken) 2019;71:1028&#x2013;1035. doi: 10.1002/acr.23734.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/acr.23734</ArticleId><ArticleId IdType="pmc">PMC6387860</ArticleId><ArticleId IdType="pubmed">30144293</ArticleId></ArticleIdList></Reference><Reference><Citation>McElhone K, Abbott J, Shelmerdine J, et al. Development and validation of a disease-specific health-related quality of life measure, the lupusQol, for adults with systemic lupus erythematosus. Arthritis Rheum. 2007;57:972&#x2013;979. doi: 10.1002/art.22881.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.22881</ArticleId><ArticleId IdType="pubmed">17665467</ArticleId></ArticleIdList></Reference><Reference><Citation>Sunbul EA, Sunbul M, Yanartas O, et al. Increased neutrophil/lymphocyte ratio in patients with depression is correlated with the severity of depression and cardiovascular risk factors. Psychiatry Investig. 2016;13:121. doi: 10.4306/PI.2016.13.1.121.</Citation><ArticleIdList><ArticleId IdType="doi">10.4306/PI.2016.13.1.121</ArticleId><ArticleId IdType="pmc">PMC4701675</ArticleId><ArticleId IdType="pubmed">26766954</ArticleId></ArticleIdList></Reference><Reference><Citation>Alsowaida N, Alrasheed M, Mayet A, et al. Medication adherence, depression and disease activity among patients with systemic lupus erythematosus. Lupus. 2017;27:327&#x2013;332. doi: 10.1177/0961203317725585.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0961203317725585</ArticleId><ArticleId IdType="pubmed">28825347</ArticleId></ArticleIdList></Reference><Reference><Citation>Taha SI, Samaan SF, Ibrahim RA, et al. Can complete blood count picture tell us more about the activity of rheumatological diseases? Clin Med Insights Arthr Musculoskelet Disord. 2022 doi: 10.1177/11795441221089182.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/11795441221089182</ArticleId><ArticleId IdType="pmc">PMC9036329</ArticleId><ArticleId IdType="pubmed">35481333</ArticleId></ArticleIdList></Reference><Reference><Citation>Abdulrahman MA, Afifi N, El-Ashry M. Neutrophil/lymphocyte and platelet/lymphocyte ratios are useful predictors comparable to serum IL6 for disease activity and damage in naive and relapsing patients with lupus nephritis. Egypt Rheumatol. 2020;42:107&#x2013;112. doi: 10.1016/J.EJR.2019.08.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/J.EJR.2019.08.002</ArticleId></ArticleIdList></Reference><Reference><Citation>Karakonstantis S, Kalemaki D, Tzagkarakis E, Lydakis C. Pitfalls in studies of eosinopenia and neutrophil-to-lymphocyte count ratio. Infect Dis (London, England) 2018;50:163&#x2013;174. doi: 10.1080/23744235.2017.1388537.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/23744235.2017.1388537</ArticleId><ArticleId IdType="pubmed">29070003</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>